Akcea: $12.5M Class Deal Reached In Ionis-Akcea Drug Licensing Suit

A class of Akcea Therapeutics Inc. stockholders told Delaware Chancery Court on Tuesday that they had reached a $12.5 million settlement with former directors and officers of the company over claims that an Ionis Pharmaceuticals deal to buy the balance of Akcea stock failed to include the value of derivative claims that Akcea, which is controlled by Ionis, paid too much to license a troubled Ionis developmental drug.